The Spiration Valve System for the Treatment of Severe Emphysema

Inclusion Criteria: 1. Patient has severe emphysema and high heterogeneity by visual assessment defined as: * a target lobe with ≥ 40% emphysema involvement and * ≥ 15% difference with the ipsilateral lobe. 2. The target lobe and ipsilateral lobe will be separated with an intact fissure. An intact fissure will be estimated visually to be ≥90% complete after viewing the HRCT in 3 dimensions. 3. Patient has received optimal medical management and it has been stable for 6 weeks prior to baseline testing. If pulmonary rehabilitation has been recent, it will be completed at least 3 months prior to baseline testing. 4. Patient must be able to demonstrate physical ability to participate in the study by performing a 6-minute walk distance of ≥ 140 m. 5. Patient has abstained from cigarette smoking for 4 months and is willing to abstain throughout the study. 6. Severe dyspnea defined as a mMRC ≥ 2. 7. Patient's obstructive disease is severe as defined by: * FEV1 ≤ 45% of predicted 8. Patient's hyperinflation is defined by: * TLC ≥ 100% of predicted * RV ≥ 150% of predicted 9. Patient is willing to participate in a study, complete the required follow-up visits, and maintain consistent nutrition and exercise habits during the study period. 10. Investigator has confirmed that medical management is within standard of care and patient has been stable and without a COPD exacerbation for 6 weeks or more. Exclusion Criteria: 1. Patient has severe gas exchange abnormalities as defined by: * PCO2 \> 50 mm Hg (6.6 kPa), or * PaO2 \< 45 mm Hg (6.0 kPa) on room air 2. Patient has a BMI \< 15 kg/m2 or \> 35 kg/m2 3. Patient is unable to provide informed consent. 4. Patient is not an appropriate candidate for or is unable to tolerate, flexible bronchoscopy procedures. 5. Patient has dysrhythmia or cardiovascular disease that poses a risk during exercise. 6. Patient has history of 4 or more hospitalizations for COPD exacerbation or respiratory infections in the past year or has had a COPD exacerbation in the 3 months prior to baseline testing. 7. Patient has bronchitis with sputum production \> 60 ml per day. 8. Patient has an active asthma component to their disease or requires more than 15 mg of prednisone daily (20 mg prednisolone). 9. Patient has giant bulla (\> 1/3 volume in either lung). 10. Patient has severe pulmonary hypertension based upon clinical evaluation. 11. A patient with a malignant condition and/or a life threatening disease (other than COPD) that would likely affect the completion of the study 12. Patient has any disease or condition that interferes with completion of initial or follow-up assessments of the effectiveness endpoints. This would include neurological or musculoskeletal conditions that may interfere with testing. 13. Patient has had prior lung volume reduction surgery or major lung procedures (lobectomy or greater). 14. Patient has a lung nodule anticipated to require evaluation or intervention during the 3 month study period. 15. Patient has demonstrated unwillingness or inability to complete screening or baseline data collection procedures. 16. Patient has a diffuse emphysema pattern, diffuse pulmonary fibrosis, or pulmonary tuberculosis (active, extensive, or with adhesive pleural incrassation). 17. Patient is classified as ASA Class greater than P4 including presence of co-morbidity that could significantly increase the risk of a bronchoscopy procedure. 18. Patient participated in a study of an investigational drug or device within the past 30 days prior to participation in this study, or is currently participating in another clinical study. 19. Female patient of childbearing potential has a positive result from a pregnancy test required during the 7 days prior to the procedure.